Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD

MC. Gonzalez, L. Oftedal, J. Lange, DA. Tovar-Rios, OB. Tysnes, C. Paquet, M. Marquié, M. Boada, D. Alcolea, K. Rejdak, E. Papuc, J. Hort, C. Falup-Pecurariu, D. Aarsland, G. Alves, J. Maple-Grødem

. 2025 ; 12 (5) : 915-924. [pub] 20250306

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25015929

Grant support
911218 Western Norway Regional Health Authority
911949 Western Norway Regional Health Authority
PI18/00435 Instituto de Salud Carlos III
PI22/00611 Instituto de Salud Carlos III
INT19/00016 Instituto de Salud Carlos III
INT23/00048 Instituto de Salud Carlos III
177966 Research Council of Norway
PERIS program SLT006/17/125 Departament de Salut, Generalitat de Catalunya
LX22NPO5107 MEYS Next Generation EU

OBJECTIVE: Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid-beta 42 (Aβ42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD. METHODS: A total of 121 DLB patients from the European-DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of GBA1 mutations (E326K, T369M, N370S, L444P), APOEε4 status, and cerebrospinal fluid (CSF) Aβ42 levels and GCase activity were assessed, as well as global cognition using the Mini-Mental State Examination. Linear mixed-effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile. RESULTS: Low CSF Aβ42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of GBA1 gene mutations or APOEε4 status. INTERPRETATION: Our study provides important evidence on the relationship between brain Aβ deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015929
003      
CZ-PrNML
005      
20250731091350.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/acn3.52295 $2 doi
035    __
$a (PubMed)40051075
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gonzalez, Maria Camila $u Department of Quality and Health Technology, Faculty of Health Sciences, University of Stavanger, Stavanger, Norway $u Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway $u Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway $1 https://orcid.org/0000000310614164
245    10
$a Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD / $c MC. Gonzalez, L. Oftedal, J. Lange, DA. Tovar-Rios, OB. Tysnes, C. Paquet, M. Marquié, M. Boada, D. Alcolea, K. Rejdak, E. Papuc, J. Hort, C. Falup-Pecurariu, D. Aarsland, G. Alves, J. Maple-Grødem
520    9_
$a OBJECTIVE: Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid-beta 42 (Aβ42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD. METHODS: A total of 121 DLB patients from the European-DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of GBA1 mutations (E326K, T369M, N370S, L444P), APOEε4 status, and cerebrospinal fluid (CSF) Aβ42 levels and GCase activity were assessed, as well as global cognition using the Mini-Mental State Examination. Linear mixed-effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile. RESULTS: Low CSF Aβ42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of GBA1 gene mutations or APOEε4 status. INTERPRETATION: Our study provides important evidence on the relationship between brain Aβ deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.
650    _2
$a lidé $7 D006801
650    12
$a glukosylceramidasa $x genetika $x metabolismus $x mozkomíšní mok $7 D005962
650    _2
$a mužské pohlaví $7 D008297
650    12
$a amyloidní beta-protein $x mozkomíšní mok $7 D016229
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a Parkinsonova nemoc $x mozkomíšní mok $x genetika $x komplikace $7 D010300
650    12
$a kognitivní dysfunkce $x mozkomíšní mok $x genetika $x etiologie $7 D060825
650    12
$a peptidové fragmenty $x mozkomíšní mok $7 D010446
650    12
$a demence s Lewyho tělísky $x mozkomíšní mok $x genetika $x komplikace $7 D020961
650    _2
$a biologické markery $x mozkomíšní mok $7 D015415
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Oftedal, Linn $u Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
700    1_
$a Lange, Johannes $u Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway $u Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway
700    1_
$a Tovar-Rios, Diego Alejandro $u Department of Quality and Health Technology, Faculty of Health Sciences, University of Stavanger, Stavanger, Norway $u Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
700    1_
$a Tysnes, Ole-Bjørn $u Department of Neurology, Haukeland University Hospital, Bergen, Norway
700    1_
$a Paquet, Claire $u Neurology Center, Assistance Publique Hôpitaux de Paris, Lariboisière Fernand-Widal Hospital, INSERMU1144, Université de Paris, Paris, France
700    1_
$a Marquié, Marta $u Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain $u CIBERNED, Center for Networked Biomedical Research On Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
700    1_
$a Boada, Mercè $u Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain $u CIBERNED, Center for Networked Biomedical Research On Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
700    1_
$a Alcolea, Daniel $u Sant Pau Memory Unit, Department of Neurology, IIB Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000238193245
700    1_
$a Rejdak, Konrad $u Department of Neurology, Medical University of Lublin, Lublin, Poland
700    1_
$a Papuc, Ewa $u Department of Neurology, Medical University of Lublin, Lublin, Poland
700    1_
$a Hort, Jakub $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Falup-Pecurariu, Cristian $u Department of Neurology, County Clinic Hospital, Faculty of Medicine, Transilvania University, Brasov, Romania
700    1_
$a Aarsland, Dag $u Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway $u Department of Psychological Medicine Institute of Psychiatry, Psychology & Neuroscience King's College London, London, UK
700    1_
$a Alves, Guido $u Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway $u Departement of Neurology, Stavanger University Hospital, Stavanger, Norway
700    1_
$a Maple-Grødem, Jodi $u Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway $u Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway
773    0_
$w MED00189500 $t Annals of clinical and translational neurology $x 2328-9503 $g Roč. 12, č. 5 (2025), s. 915-924
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40051075 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091344 $b ABA008
999    __
$a ok $b bmc $g 2366638 $s 1253054
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 12 $c 5 $d 915-924 $e 20250306 $i 2328-9503 $m Annals of clinical and translational neurology $n Ann Clin Transl Neurol $x MED00189500
GRA    __
$a 911218 $p Western Norway Regional Health Authority
GRA    __
$a 911949 $p Western Norway Regional Health Authority
GRA    __
$a PI18/00435 $p Instituto de Salud Carlos III
GRA    __
$a PI22/00611 $p Instituto de Salud Carlos III
GRA    __
$a INT19/00016 $p Instituto de Salud Carlos III
GRA    __
$a INT23/00048 $p Instituto de Salud Carlos III
GRA    __
$a 177966 $p Research Council of Norway
GRA    __
$a PERIS program SLT006/17/125 $p Departament de Salut, Generalitat de Catalunya
GRA    __
$a LX22NPO5107 MEYS $p Next Generation EU
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options